Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

781 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases.
Lunger L, Steinhelfer L, Korn P, Eiber M, Maurer T, Büchler J, Horn T, Gschwend JE, Heck MM. Lunger L, et al. Among authors: horn t. Eur Urol Oncol. 2023 Feb;6(1):95-98. doi: 10.1016/j.euo.2022.12.001. Epub 2023 Jan 4. Eur Urol Oncol. 2023. PMID: 36604297
Biochemical Response of <0.1 ng/ml Predicts Therapy-free Survival of Prostate Cancer Patients following Prostate-specific Membrane Antigen-targeted Salvage Surgery.
Knipper S, Lischewski F, Koehler D, Eiber M, van Leeuwen FWB, de Barros H, Berrens AC, Zuur L, van Leeuwen PJ, van der Poel H, Ambrosini F, Falkenbach F, Budäus L, Steuber T, Graefen M, Tennstedt P, Gschwend JE, Horn T, Heck MM, Maurer T. Knipper S, et al. Among authors: horn t. Eur Urol Oncol. 2024 May 9:S2588-9311(24)00112-3. doi: 10.1016/j.euo.2024.04.019. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38729805 Free article.
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF; LIGHTHOUSE Study Group. Surasi DS, et al. Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414702 Free article.
MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease.
Slotta-Huspenina J, Schwamborn K, Steiger K, Simon R, Kirchhoff FP, Büchler JW, Fiedler J, Retz M, Nawroth R, Ritschel C, Gschwend JE, Horn T. Slotta-Huspenina J, et al. Among authors: horn t. Bladder Cancer. 2022 Sep 15;8(3):269-276. doi: 10.3233/BLC-211604. eCollection 2022. Bladder Cancer. 2022. PMID: 38993685 Free PMC article.
Commensal papillomavirus immunity preserves the homeostasis of highly mutated normal skin.
Son HG, Ha DT, Xia Y, Li T, Blandin J, Oka T, Azin M, Conrad DN, Zhou C, Zeng Y, Hasegawa T, Strickley JD, Messerschmidt JL, Guennoun R, Erlich TH, Shoemaker GL, Johnson LH, Palmer KE, Fisher DE, Horn TD, Neel VA, Nazarian RM, Joh JJ, Demehri S. Son HG, et al. Among authors: horn td. Cancer Cell. 2025 Jan 13;43(1):36-48.e10. doi: 10.1016/j.ccell.2024.11.013. Epub 2024 Dec 12. Cancer Cell. 2025. PMID: 39672169
781 results